TECX
NASDAQ HealthcareTectonic Therapeutic, Inc. - Common Stock
Biotechnology
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
๐ Market Data
| Price | $30.65 |
|---|---|
| Volume | 162,808 |
| Market Cap | 578.34M |
| Beta | 0.100 |
| RSI (14-Day) | 49.1 |
| 200-Day MA | $24.62 |
| 50-Day MA | $30.57 |
| 52-Week High | $39.53 |
| 52-Week Low | $14.39 |
| Forward P/E | -6.55 |
| Price / Book | 2.50 |
๐ฏ Investment Strategy Scores
TECX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ฐ Dividend Daddy (51/100) โ this strategy High dividend yield + low volatility.
Lowest fit among scored strategies: ๐ Institutional Whale (14/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find TECX in your text
Paste any article, transcript, or post โ the tool will extract TECX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.